The independent source for health policy research, polling, and news.
2,681 - 2,700 of 3,950 Results
A voucher awarded to companies that find treatments for rare childhood diseases can be sold to the highest bidder — and then used to speed up approvals for much more common drugs.
Researchers examine the Food and Drug Administration’s “revolving door” regarding employees who worked on cancer and hematology drugs.
A pilot project involving Swedish Medical Center and the Neighborcare Health network of community clinics offers care for uninsured adults or those on Medicaid.
The flu vaccine is available for longer windows of time. Experts say to weigh convenience and science in deciding when to roll up your sleeve.
Based on lessons learned in the 2014 Ebola outbreak, the federal agency has designated teams to help identify patients and health care workers who have been exposed to the virus.
Doctors are concerned that requiring referrals to genetic counselors can deter women from going forward with testing for genetic mutations that cause breast cancer.
Based on an analysis of insurance company payments, emergency room visits and lab tests were responsible for much of the overall spending.
Researchers at the University of California, San Francisco estimate that hospitals could lose nearly $1,000 per surgery by throwing away opened but unused supplies, such as gloves and sponges.
Consumers Union says Anthem Inc. and Blue Shield of California may be exploiting furor over prescription drug prices. State regulators are looking into the issue.
A closer look shows that industry lobbying was just one factor in EpiPen’s sales explosion.
A federally funded research project in Baltimore has potential to help aging-in-place efforts elsewhere, a study in Health Affairs reports.
Researchers writing in Health Affairs report that decisions by 19 states to not expand the program for low-income residents could be hurting the financial stability of rural hospitals.
A study in Health Affairs concludes that orphan drugs for rare diseases are not having a widespread or deep impact on health care spending.
Four years after a huge push to speed generics to market, the FDA has more than 4,000 generics waiting for approval.
Under a new state law, California consumers could get money back if they were charged out-of-network prices after going to a medical provider who was listed in their health plan’s network.
A partnership between San Diego County and four health systems seeks to bridge the longstanding gap between hospitals and social services.
Research to be published in full this fall details how medicine’s “implicit bias” — whether real or perceived — undermines the doctor-patient relationship and the well-being of racial and ethnic minorities as well as lower-income patients.
A new study examines how well efforts are working that prioritize the needs of these patients if they end up needing a kidney transplant of their own.
As news that Mylan will make available a generic version of its own brand-name product, KHN answers key questions about how this development could affect consumers.
Older people are often given a huge number of medications, and many of them are unnecessary or even harmful.
© 2026 KFF